Treatment of cognitive disorders in dementia syndromes (except for Alzheimer's disease). Treatment of cortical myoclonus.
Composition:
One container (60 ml) contains 12 g of piracetam. 1 ampoule of 15 ml contains 3 g, 1 ampoule of 5 ml contains 1 g of piracetam.
Action:
Nootropic drug - a cyclic derivative of gamma-aminobutyric acid (GABA). Piracetam protects and restores cognitive abilities in patients with various types of brain damage. Piracetam initiates the process of reconstructing the membrane structure, which improves its stability. Piracetam acts on nerve cells and the vascular system. In neurons, piracetam has a variety of effects on cell membranes. The drug does not bind to plasma proteins. It penetrates the blood-brain barrier, the maximum concentration in the cerebrospinal fluid is reached after about 5 hours, and T0,5 in the cerebrospinal fluid is about 8.5 hours. It is not metabolised in the body. It is excreted mainly in urine in unchanged form. T0,5 is about 5 hours.
Contraindications:
Hypersensitivity to Piracetam, other pyrrolidone derivatives or any of the excipients. Severe renal failure (renal creatinine clearance less than 20 ml / min). Brain hemorrhage. Substantial psychomotor stimulation. Huntington's chorea.
Precautions:
The preparation should be used with caution in patients with impaired renal function, with impaired hemostasis, undergoing major surgery, and in patients with severe hemorrhage, in elderly patients and in patients with very low blood pressure. Do not suddenly stop taking piracetam in patients with myoclonus because the risk of epileptic seizures increases.
Pregnancy and lactation:
The drug should not be used during pregnancy, or in women planning pregnancy. Avoid piracetam during breastfeeding or stop breastfeeding during treatment.
Side effects:
Common: hyperkinesia, weight gain, nervousness. Uncommon: drowsiness, depression, asthenia. Frequency unknown: dizziness, nausea, vomiting, diarrhea, abdominal pain, epigastric pain, ataxia, balance disorders, epilepsy severity, headache, insomnia, drowsiness, agitation, anxiety, confusion, hallucinations, angioneurotic edema, dermatitis , pruritus, urticaria, anaphylactoid reactions, hypersensitivity. There have been rare reports of pain at the injection site, phlebitis with thrombosis, fever or hypotension after intravenous administration.
Dosage:
Intravenous infusion.Treatment of cognitive disorders: 4.8 g / day for the first weeks of treatment, then reduce the dose to 2.4 g / day. The daily dose is given in 2 or 3 divided doses. The dose should be reduced by 1.2 g / day.Treatment of cortical myoclonus: Initially 7.2 g per day. If necessary, the dose is increased every four to four days by 4.8 g a day, up to a maximum dose of 24 g a day. The daily dose is given in 2 or 3 divided doses. In combination with other antimusconics, doses of other medicines should be maintained at the recommended therapeutic dose. If a clinical improvement is achieved and it is possible - doses of other drugs should be reduced. People with myoclonus may occasionally develop symptoms, so every 6 months should try to reduce the dose or discontinuation of the drug. For this purpose, the dose should be reduced by 1.2 g every 2 days to prevent sudden relapse. Patients with renal insufficiency: at a creatinine clearance of 40-60 ml / min should be used 1/2 dose, at a clearance of 20-40 ml / min - 1/4 dose, in patients with a creatinine clearance below 20 ml / min the drug is contraindicated.
(C)
